Novavax Inc vs Nova Ltd — how do they compare? Novavax Inc trades at $9.88 (market cap $1.68B), while Nova Ltd trades at $375.01 (market cap $11.99B). The key difference: Nova Ltd is far larger — about 7.1× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Nova Ltd nearer its low. Which is the better fit depends on your goals.
| NVAX | NVMI | |
|---|---|---|
Market Cap | $1.68B | $11.99B |
Sector | Health | Technology |
52-Week High | $11.19 | $605.65 |
52-Week Low | $6.22 | $275.78 |
Enterprise Value | $1.26B | $11.78B |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.
The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Nova provides metrology solutions for semiconductor manufacturing. Its systems measure material and process characteristics to help chipmakers control production across advanced nodes and packaging.
Read more on NVMI →